Photo by nci from unsplash
The prognosis is poor for patients who have relapsed‐refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first‐salvage AML or in studies that were conducted before… Click to show full abstract
The prognosis is poor for patients who have relapsed‐refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first‐salvage AML or in studies that were conducted before 2000. Several novel agents and strategies are being tested for potential approval as treatment for patients with relapsed‐refractory AML in second salvage. Therefore, it is important to establish the historic results of anti‐AML therapies in this setting in the modern era. The objective of the current study was to analyze the results from second salvage therapies in patients with AML since 2000 with regard to response and survival.
Journal Title: Cancer
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!